NEW YORK: The U.S. on Thursday authorized Merck & Co's (MRK.N) antiviral pill for COVID-19 for certain high-risk adult patients, a day after giving a broader go-ahead to a similar but more effective treatment from Pfizer Inc (PFE.N).
The US Food and Drug Administration said Merck's drug could be used when other authorised treatments are not accessible or clinically appropriate.
The drug, molnupiravir, was developed with Ridgeback Biotherapeutics and shown to reduce hospitalizations and deaths by around 30% in a clinical trial of high-risk individuals early in the course of the illness.
The authorization allows use of the drug for mild-to-moderate COVID-19 and along with the Pfizer pill, could be an important tool against the fast-spreading Omicron variant, which is now dominant in the United States.
Pfizer's drug, Paxlovid, was authorised on Wednesday for people aged 12 and older and has shown to be nearly 90% effective in preventing hospitalisations and deaths in patients at high risk of severe illness, according to trial data. read more
The FDA says some patients should avoid Pfizer's two-drug regimen because it includes an older antiviral called ritonavir that is known to have interactions with some other prescription medicines. It is also not recommended for people with severe kidney issues.
Merck plans to ship hundreds of thousands of treatment courses in coming days and 1 million over the next few weeks. Pfizer plans to ship about 250,000 courses in the next month.
Availability of other treatments is the first consideration for doctors thinking of prescribing Merck's treatment, according to Patrizia Cavazzoni, the director of FDA's Center for Drug Evaluation and Research. read more
The FDA has authorized intravenous treatments, mostly for hospital use, called monoclonal antibodies but availability is limited and efficacy against the Omicron variant is lower.
FDA official John Farley said during a press briefing that GlaxoSmithKline's (GSK.L) and Vir Biotech's (VIR.O) antibody drug - which has been shown to work against Omicron - is expected to be in short supply this winter.
Merck said that its treatment had advantages over the Pfizer pill.
"It doesn't require any second drug to boost its efficacy, and you can give it in a variety of special patient populations, including people who have significant issues with liver function or kidney function," Nick Kartsonis, Merck's senior vice president of clinical research for vaccines and infectious diseases, told Reuters.
"This approval comes at the right time since more COVID-19 treatments are needed to supplement the vaccination effort, especially in light of variants of concern," said Cantor Fitzgerald analyst Louise Chen.
Nearly 62% of people in the United States are fully vaccinated, leaving many Americans unprotected against a wave of Omicron infections. Two doses of the highly successful vaccine from Pfizer Inc and BioNTech SE are only somewhat protective against infection with the Omicron variant while a third dose improves the immune response.
Merck's and Pfizer's antiviral both work by preventing the virus from replicating. Merck's pill does so by introducing errors into the genetic code of the virus.
Some of the FDA's experts have said that could lead to more troublesome variants.
There have also been some safety concerns around the drug because it may affect bone cartilage and growth.
Due to that reason, Merck's drug is not authorized for use in patients younger than 18, the FDA said. The pill is not recommended for use during pregnancy, the agency added.
The agency advised that men of reproductive potential use a reliable method of birth control during treatment with molnupiravir, and for at least three months after the final dose.
The drug is meant to be taken twice a day - four pills each time - for five days, making a full treatment course 40 pills. The treatment was priced at about $700 per course in a deal with the U.S. government for up to 5 million courses.
The U.S. government has ordered 10 million courses of the Pfizer drug at a price of $530 per course compares to the deal with Merck for as many as 5 million courses of molnupiravir at a price of $700 per course.
Merck has said molnupiravir, which helps prevent the virus from replicating, should be effective against any variant, including the new Omicron variant.
Reuters
Fri Dec 24 2021
Merck plans to ship hundreds of thousands of treatment courses in the coming days and 1 million over the next few weeks. - REUTERS photo
Ahli ekonomi yakin pertumbuhan KDNK sekitar 5.8 peratus pada suku kedua 2024
Kalangan ahli ekonomi yakin KDNK Malaysia bagi suku kedua 2024 akan berkembang pada 5.8 peratus berbanding 4.2 peratus pada suku pertama tahun ini.
Cisco akan kurangkan 7 peratus tenaga kerja globalnya
Langkah mengurangkan kakitangan itu dijangka melibatkan kos pra-cukai sehingga AS$1 bilion.
Jiwa SME: Kuih tradisonal sejuk beku 'diterbangkan' ke Tanah Suci
Inovasi pembuatan makanan sejuk beku, terutama kuih muih tradisional telah berjaya membawa produk itu ke peringkat global, terutama dalam memenuhi citarasa jemaah haji dan umrah rakyat Malaysia di Tanah Suci Mekah dan Madinah.
Gol sulung Mbappe bantu Real Madrid juarai Piala Super UEFA
"Ia adalah malam yang hebat. Ia adalah detik yang hebat untuk saya. Dan kami memenangi kejuaraan, yang penting - di Madrid anda perlu sentiasa menang."
“I love you Am, bahagialah di syurga firdausi” - Aufahanie
Air mata Aufahanie sudah kering meratapi pemergian abang tercinta, Nidza Afham yang ditemui meninggal dunia selepas dilaporkan hilang.
Konsert jelajah: Taylor Swift teruskan konsert London selepas ancaman keganasan
Taylor Swift akan meneruskan persembahan di London pada Khamis, meneruskan jelajah konsert terbesar dunia di tengah-tengah kebimbangan keselamatan susulan cubaan serangan Daesh memaksa pembatalan tarikh konsert di Vienna, minggu lalu.
Taliban rai ulang tahun ketiga pemerintahan Afghanistan
Kerajaan Taliban semalam meraikan ulang tahun ketiga pemerintahannya di Afghanistan dengan perarakan tentera yang memberi penghormatan kepada bom buatan sendiri yang digunakan ketika peperangan, pesawat pejuang dan perbarisan pasukan keselamatan.
Bapa bintang bola sepak Sepanyol, Lamine Yamal ditikam - Laporan
Mounir Nasraoui, bapa kepada Lamine Yamal, ditikam pada lewat Rabu di tempat letak kereta di bandar Mataro di timur laut Sepanyol.
Warga AS dihukum penjara 15 hari di Rusia kerana bersikap samseng
Mahkamah Moscow menjatuhkan hukuman penjara 15 hari kepada warga Amerika Syarikat Joseph Tater pada Rabu kerana bersikap samseng.
Putin anggap rundingan dengan Ukraine tidak berguna
Presiden Rusia Vladimir Putin menyifatkan, tindakan Ukraine yang menyerang orang awam memperlihatkan keengganan Kyiv menyelesaikan konflik peperangan dua negara dengan cara perdamaian.
Berita antarabangsa pilihan sepanjang hari ini
Antara pelbagai berita luar negara yang disiarkan di Astro AWANI, berikut adalah antara yang paling menjadi tumpuan sepanjang hari ini.
Tahap pengurusan rantaian bekalan akan dipertingkat - PM Anwar
Mesyuarat MPN Ke-6 Tahun 2024 hari ini bersetuju dengan beberapa langkah bagi meningkatkan tahap pengurusan rantaian bekalan yang kukuh, berdaya tahan dan responsif kepada gangguan.
Olimpik Paris: Lyles raih gangsa acara 200m lelaki, meskipun positif COVID-19
Lyles terpaksa berpuas hati dengan pingat gangsa dalam acara 200m, dengan emas menjadi milik atlet Botswana, Letsile Tebogo.
[KOLUMNIS] Bahaya maklumat salah: Ancaman keamanan dan keharmonian di Malaysia
Maklumat yang salah bukan sahaja ancaman di negara-negara Barat tetapi juga semakin menjadi masalah besar di Malaysia.
KKM belanja RM137 juta setahun bagi menyelenggara 201 klinik kesihatan
KKM membelanjakan sebanyak RM137 juta setahun bagi menyelenggara 201 buah klinik kesihatan di seluruh negara di bawah PSK dengan kontrak selama 5 tahun bermula tahun 2022.
Olimpik Paris 2024: Atlet renang Australia tarik diri selepas positif COVID-19
Atlet renang Australia Lani Pallister terpaksa menarik diri dari acara bebas 1,500 meter selepas positif COVID-19, menurut pasukan negara itu pada Selasa.
Biden kembali ke Rumah Putih selepas beberapa hari pengasingan COVID-19
Presiden Amerika Syarikat (AS) Joe Biden tiba semula di Rumah Putih pada Selasa selepas beberapa hari diasingkan akibat COVID-19 dan di tengah-tengah khabar angin mengenai kesihatannya.
Gantung Parlimen: 2 wakil rakyat dibenar mulakan semakan kehakiman
Mahkamah Persekutuan membenarkan dua wakil rakyat memulakan semakan kehakiman bagi mencabar nasihat Muhyiddin untuk menggantung Parlimen sepanjang tempoh darurat pandemik COVID-19.
Biden pulih daripada gejala COVID-19, ujian negatif
Ujian antigen pantas BINAX adalah negatif, bagaimanapun, beliau akan terus dipantau untuk sebarang penyakit berulang.
Biden alami gejala COVID-19 ringan, ambil ubat antiviral
Kevin O'Connor berkata gejala yang dialami presiden itu mempengaruhi sistem pernafasannya.